Tucker P Collins

US Patent:

6972175, Dec 6, 2005

Filed:

Nov 27, 2002

Appl. No.:

10/305504

Inventors:

David Pinsky - Ann Harbor MI, US
Tucker Collins - Cohasset MA, US

International Classification:

C12Q001/68
C12Q001/02

US Classification:

435 6, 435 29

Abstract:

This invention provides methods for determining whether an agent increases PPAR-γ-mediated inhibition of Egr-1 expression. This invention also provides methods for inhibiting the onset of atherosclerosis in a transplanted organ. This invention further provides numerous methods for treating disorders, and/or inhibiting the onset of disorders or disorder-related complications by using PPAR-γ agonists. This invention still further provides related methods for inhibiting cancer metastasis, treating and inhibiting the onset of a heart attack, and treating burn and crush injuries. Finally, this invention provides related articles of manufacture.

US Patent:

57081476, Jan 13, 1998

Filed:

Jun 16, 1994

Appl. No.:

8/261304

Inventors:

Michael A. Gimbrone - Boston MA
Myron I. Cybulsky - Allston MA
Tucker Collins - Cohasset MA

Assignee:

Brigham & Women's Hospital - Boston MA

International Classification:

C07K 1400

US Classification:

5303887

Abstract:

The invention relates to novel endothelial cell-leukocyte adhesion molecules designated ATHERO-ELAM. ATHERO-ELAM molecules are expressed on cultured endothelial cells stimulated with bacterial LPS and selectively mediate the binding of monocytes to the endothelial cells. Monoclonal antibodies specific for ATHERO-ELAM bind to vascular endothelial cells involved in early atherosclerotic lesions, but not to vascular endothelial cells from uninvolved arterial tissue. ATHERO-ELAM and antibodies directed to ATHERO-ELAM may be used in identifying early atherosclerotic lesions and in treating and preventing atherosclerosis.